Nick Paul Taylor

Biography for Nick Paul Taylor

Nick Taylor, UK Correspondent

Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at ntaylor@fiercemarkets.com and follow him on Twitter at @NickPaulTaylor.

Articles by Nick Paul Taylor

100,000 Genomes Project taps Big Pharma dream team for data crunching skills

The United Kingdom has wasted no time getting industry involved with its 100,000 Genomes Project. With just 3% of the sequencing work done, Genomics England has enlisted the help of a who's who of Big Pharma companies to pore over the data in search of new avenues for drug discovery.

Amgen's deCODE lays marker for future of genomics-driven drug discovery

Amgen's deCODE Genetics has released a glimpse of a future in which population-scale genome sequencing forms the basis of drug discovery programs. And while the initiative still has some technical shortcomings and has yet to prove to the outside world it is worth $415 million, it nonetheless sparked excitement in the genomics community.

India crowdsources whistleblowing with website, mobile app

India has given consumers a way to complain about the availability or pricing of drugs. By providing an online portal and mobile app through which consumers can vent their grievances, Indian authorities are trying to turn the country's vast population into a disaggregated army of whistleblowers.

Big Pharma nervously eying Apple and Google's healthcare pitches

The Financial Times has taken a look at the implications of Apple and Google's ever-growing interest in healthcare and life sciences.

FDA under pressure to establish staff social media policy

Having faced years of criticism for its failure to publish guidelines on how the industry can use social media, the FDA is now being chastised by the advocacy group Union of Concerned Scientists over its lack of a policy for its staff.

Cloud Pharmaceuticals allies with U. of Florida to advance in silico pipeline

Cloud Pharmaceuticals has taken the next step in its push to create a pipeline of drugs discovered using a computer-based design process, hooking up with the University of Florida to transition its computer-discovered drugs into traditional preclinical research.

AstraZeneca taps Assay Depot to create preclinical service hub

The list of IT vendors and service providers that have yet to strike a deal with AstraZeneca in 2015 keeps getting shorter. Assay Depot is the latest name to cross of the list after the scientific services marketplace agreed to create a private research e-commerce platform for AstraZeneca.

Nimbus bags $43M from Big Pharma VCs to test computer-designed drugs

Nimbus Therapeutics is ready to see how the compounds it discovered with the help of Schrödinger's computational chemistry tools fare in the clinic. And the VC units of Eli Lilly, GlaxoSmithKline and Pfizer want to find out, too, prompting each to chip in to Nimbus' $43 million Series B round.

UCB to host epilepsy digital tool hackathon

UCB is hosting a hackathon focused on developing new tools to improve the day-to-day lives of people with epilepsy and their families, PMLiVE reports.

Google adds Tute database to burgeoning Genomics platform

Google has added another publicly available database to its growing Genomics platform. The latest deal sees Google Genomics host Tute Genomics' repository of 8.5 billion annotations of genetic variants, giving users another resource to probe with the tech giant's growing arsenal of data integration tools.